Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells.

Polycomb-repressive complex 2 (PRC2)-mediated histone methylation plays an important role in aberrant cancer gene silencing and is a potential target for cancer therapy. Here we show that S-adenosylhomocysteine hydrolase inhibitor 3-Deazaneplanocin A (DZNep) induces efficient apoptotic cell death in cancer cells but not in normal cells. We found that DZNep effectively depleted cellular levels of PRC2 components EZH2, SUZ12, and EED and inhibited associated histone H3 Lys 27 methylation (but not H3 Lys 9 methylation). By integrating RNA interference (RNAi), genome-wide expression analysis, and chromatin immunoprecipitation (ChIP) studies, we have identified a prominent set of genes selectively repressed by PRC2 in breast cancer that can be reactivated by DZNep. We further demonstrate that the preferential reactivation of a set of these genes by DZNep, including a novel apoptosis affector, FBXO32, contributes to DZNep-induced apoptosis in breast cancer cells. Our results demonstrate the unique feature of DZNep as a novel chromatin remodeling compound and suggest that pharmacologic reversal of PRC2-mediated gene repression by DZNep may constitute a novel approach for cancer therapy.

[1]  A. Klein-Szanto,et al.  Phosphorylation-Dependent Ubiquitination of Cyclin D1 by the SCFFBX4-αB Crystallin Complex , 2006 .

[2]  Anke Sparmann,et al.  Polycomb silencers control cell fate, development and cancer , 2006, Nature Reviews Cancer.

[3]  Akinobu Matsumoto,et al.  Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin‐dependent degradation , 2006, Cancer science.

[4]  J. Zeitlinger,et al.  Polycomb complexes repress developmental regulators in murine embryonic stem cells , 2006, Nature.

[5]  Kristian Helin,et al.  Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. , 2006, Genes & development.

[6]  C. Holden.  Gene-Suppressing Proteins Reveal Secrets of Stem Cells , 2006, Science.

[7]  James A. Cuff,et al.  A Bivalent Chromatin Structure Marks Key Developmental Genes in Embryonic Stem Cells , 2006, Cell.

[8]  Megan F. Cole,et al.  Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells , 2006, Cell.

[9]  Kevin K. Yang,et al.  Apoptosis Signal-regulating Kinase 1 Is a Direct Target of E2F1 and Contributes to Histone Deacetylase Inhibitorinduced Apoptosis through Positive Feedback Regulation of E2F1 Apoptotic Activity* , 2006, Journal of Biological Chemistry.

[10]  L. Bystrykh,et al.  The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. , 2006, Blood.

[11]  M. Fraga,et al.  The Polycomb group protein EZH2 directly controls DNA methylation , 2006, Nature.

[12]  S. Baylin,et al.  Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? , 2006, Nature Reviews Cancer.

[13]  B. Panning,et al.  The Polycomb group protein Eed protects the inactive X-chromosome from differentiation-induced reactivation , 2006, Nature Cell Biology.

[14]  藤井 洋.  Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation , 2006 .

[15]  V. Pirrotta.  Polycomb silencing mechanisms and genomic programming. , 2006, Ernst Schering Research Foundation workshop.

[16]  Peter A. Jones,et al.  Epigenetic therapy of cancer: past, present and future , 2006, Nature Reviews Drug Discovery.

[17]  John K Field,et al.  Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  E. Liu,et al.  Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  B. Clurman,et al.  Mechanisms of Tumor Suppression by the SCFFbw7 , 2005, Cell cycle.

[20]  Stormy J. Chamberlain,et al.  The Murine Polycomb Group Protein Eed Is Required for Global Histone H3 Lysine-27 Methylation , 2005, Current Biology.

[21]  M. Fraga,et al.  Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer , 2005, Nature Genetics.

[22]  D. Reinberg,et al.  Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  G. Peters,et al.  Role of polycomb group proteins in stem cell self-renewal and cancer. , 2005, DNA and cell biology.

[24]  C. Monneret,et al.  Histone deacetylase inhibitors. , 2005, European journal of medicinal chemistry.

[25]  L. Altucci,et al.  Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells , 2005, Nature Medicine.

[26]  B. Clurman,et al.  A Nucleolar Isoform of the Fbw7 Ubiquitin Ligase Regulates c-Myc and Cell Size , 2004, Current Biology.

[27]  Kristian Helin,et al.  Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity , 2004, The EMBO journal.

[28]  Stuart S Levine,et al.  Division of labor in polycomb group repression. , 2004, Trends in biochemical sciences.

[29]  Gangning Liang,et al.  Preferential response of cancer cells to zebularine. , 2004, Cancer cell.

[30]  Yi Zhang,et al.  SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. , 2004, Molecular cell.

[31]  D. Reinberg,et al.  Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. , 2004, Genes & development.

[32]  A. Lund,et al.  Polycomb complexes and silencing mechanisms. , 2004, Current opinion in cell biology.

[33]  Qiang Yu,et al.  p53-regulated Transcriptional Program Associated with Genotoxic Stress-induced Apoptosis* , 2004, Journal of Biological Chemistry.

[34]  G. Yancopoulos,et al.  The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. , 2004, Molecular cell.

[35]  A. Feinberg,et al.  The history of cancer epigenetics , 2004, Nature Reviews Cancer.

[36]  J. Kennison.  Introduction to Trx-G and Pc-G genes. , 2004, Methods in enzymology.

[37]  Kristian Helin,et al.  EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer , 2003, The EMBO journal.

[38]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  En Li,et al.  Suv 39 h-Mediated Histone H 3 Lysine 9 Methylation Directs DNA Methylation to Major Satellite Repeats at Pericentric Heterochromatin , 2003 .

[40]  Arul M Chinnaiyan,et al.  Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. , 2003, Journal of the National Cancer Institute.

[41]  P. Farnham,et al.  Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. , 2003, Molecular cancer therapeutics.

[42]  Toshiki Mori,et al.  ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. , 2002, Molecular cell.

[43]  Thomas A Milne,et al.  MLL targets SET domain methyltransferase activity to Hox gene promoters. , 2002, Molecular cell.

[44]  M. Loda,et al.  The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer? , 2002, Cancer cell.

[45]  Christian Beisel,et al.  Histone methylation by the Drosophila epigenetic transcriptional regulator Ash1 , 2002, Nature.

[46]  Brigitte Wild,et al.  Histone Methyltransferase Activity of a Drosophila Polycomb Group Repressor Complex , 2002, Cell.

[47]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[48]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.

[49]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[50]  Peter A. Jones,et al.  Cell division is required for de novo methylation of CpG islands in bladder cancer cells. , 2002, Cancer research.

[51]  Karl Mechtler,et al.  Loss of the Suv39h Histone Methyltransferases Impairs Mammalian Heterochromatin and Genome Stability , 2001, Cell.

[52]  C. Ponting,et al.  Regulation of chromatin structure by site-specific histone H3 methyltransferases , 2000, Nature.

[53]  M. Bray,et al.  Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. , 2000, Antiviral research.

[54]  A. Otte,et al.  Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation , 1999, Nature Genetics.

[55]  V. Pirrotta.  Polycomb silencing and the maintenance of stable chromatin states. , 1999, Results and problems in cell differentiation.

[56]  R K Gordon,et al.  S‐Adenosylmetliionine and methylation , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[57]  J. Kennison.  The Polycomb and trithorax group proteins of Drosophila: trans-regulators of homeotic gene function. , 1995, Annual review of genetics.

[58]  M. Wolfe,et al.  Rational approaches to the design of antiviral agents based on S-adenosyl-L-homocysteine hydrolase as a molecular target. , 1992, Antiviral research.

[59]  P. Chiang,et al.  Activation of collagen IV gene expression in F9 teratocarcinoma cells by 3-deazaadenosine analogs. Indirect inhibitors of methylation. , 1992, The Journal of biological chemistry.

[60]  E. De Clercq,et al.  Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5'-nor derivatives , 1989, Antimicrobial Agents and Chemotherapy.

[61]  M. Hollingshead,et al.  Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities. , 1989, Journal of medicinal chemistry.

[62]  A. Razin,et al.  Relationship between transient DNA hypomethylation and erythroid differentiation of murine erythroleukemia cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[63]  R. I. Glazer,et al.  3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. , 1986, Biochemical and biophysical research communications.

[64]  P. Chiang.  Conversion of 3T3-L1 fibroblasts to fat cells by an inhibitor of methylation: effect of 3-deazaadenosine. , 1981, Science.

[65]  P. Chiang,et al.  Perturbation of biochemical transmethylations by 3-deazaadenosine in vivo. , 1979, Biochemical pharmacology.